


Roche at a Glance An Introduction to our Company


February 2013



Basic facts at a glance







- Founded 1896 in Basel, Switzerland
- Founding families still hold majority stake
- Employing 80,000 people
- Currently active in 150 countries on all continents
- Sales 2011: 42.5 billion Swiss Francs
- Clear focus on healthcare
- Leadership in pharmaceuticals (#5)*
- World's largest biotech company with truly differentiated medicines in oncology, virology, inflammation, metabolism and CNS
- Leadership in in vitro diagnostics (#1) and pioneer in diabetes management
- Unique innovation model



Basic facts at a glance

Focusing on innovative Pharmaceuticals and Diagnostic tests

- Our aim is to discover, develop and market innovative solutions that bring clear medical benefit in disease areas with high unmet medical need
 - Oncology (e.g. breast, cervical, colon cancer)
 - Virology (e.g. hepatitis, HIV)
 - Inflammation and autoimmune disorders (e.g. rheumatoid arthritis, asthma)
 - Cardiovascular and metabolic disorders (e.g. diabetes)
 - Central Nervous System (e.g. Alzheimer's)
- Our products and services help to prevent, diagnose and treat diseases, thus enhancing people's health and quality of life




















More than 116 years of Roche *Historical timeline*

Personalised Healthcare



Roche Group Structure



Pharma

Diagnostics

Roche

Professional





Roche



Roche

Molecular






Roche

Tissue






Personalised Healthcare (PHC) - driver of change Key to enabling highly differentiated medicines





Roche strategy

Focused on medically differentiated therapies



Differentiation



Biomarker to guide treatment decisions Diseases requiring sub-group identification

Metastatic breast cancer


15 – 25% HER2 positive

Non-small cell lung cancer

10 – 30% EGFR positive

Non-small cell lung cancer

~ 50% cMET positive



Asthma

~ 50% Periostin positive

Stomach cancer

16 – 22% HER2 positive

Metastatic melanoma

~ 50% BRAF positive



Roche already offers a range of examples Targeted therapies - approved



Oncology

- Breast- and stomach cancer: Herceptin for patients with HER2-positive cancer
- Metastatic melanoma (skin cancer): Zelboraf for patients with BRAF-positive metastatic melanoma
- Lung cancer: Tarceva first-line treatment for patients with EGFR-positive non-small lung cancer

Virology


- Hepatitis B and C infections: Pegasys (HBV) and Pegasys/Copegus (HCV), genotype and viral load testing
- HIV: Invirase/ Viracept/ Fuzeon, viral load testing

Diagnosis

Providing biomarkers and diagnostic tests




Our approach to Pharma innovation Diversity of approaches fueling global scale and reach





NME submissions and their additional indications *Projects currently in phase 2 and 3*



Unless stated otherwise, submissions are planned to occur in US and EU.
✓ indicates a submission which has occurred with regulatory action pending # negative symptoms and sub-optimal control





Roche Values Standards that guide daily behaviour and decisions

Integrity

We embrace differences and are consistently open, honest, ethical and genuine.

Courage

We are entrepreneurial and thus take risks, reach beyond boundaries, and experiment.

Passion

We use our drive and commitment to energize engage and inspire others.



Sustainability is integral to the way we do business *Humanitarian*, cultural and educating projects



- Phelophepa Healthcare Train in South Africa
- Roche Children's Walk
- Roche Employee Action and Charity Trust (Re&Act)



- Roche Commissions
- Roche Continents
- Roche 'n' Jazz / Museum Tinguely



- Roche Postdoc Fellowship Programme
- Science programme for pupils
- Schweizer Jugend forscht



We Innovate Healthcare